Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BDB001 (EIK1001) as monotherapy and in combination with pembrolizumab in advanced solid tumors
NCT03486301Phase 1Completed
- Sponsor
- Eikon Therapeutics
- Start
- Feb 2018
- Primary completion
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BDB001 in solid tumor (2 arms), sponsored by Eikon Therapeutics. Primary endpoints: Adverse Events at 30 months and Dose Limiting Toxicity at 30 months. Started Feb 2018; status: completed.
02
Drugs
BDB001
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03486301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03486301.